Healthcare entity
acquisition is the sole category represented across all 1 tracked stories. Novartis AG is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 6.3 in the same window.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
acquisition is the sole category represented across all 1 tracked stories. Novartis AG is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 8 average consequence score is above the beat benchmark of 6.3 in the same window. They are better corroborated than the beat average, carrying 3 original sources each against 2.9 for the same window. SNV4818 appears in 1 tracked Healthcare story from March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SNV4818. Shared-story counts are live from our verified record — not editorial picks.
Novartis AG has entered into a definitive agreement to acquire an experimental breast cancer drug candidate, SNV4818, from Delaware-based Synnovation Therapeutics for up to $3 billion. This strategic acquisition aims to strengthen Novartis's leadership in the oncology market as it continues its pivot toward high-value innovative medicines.
Source: Seeking Alpha · Bloomberg
SNV4818 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
